Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 101–200 of 1,001
Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic
Barh, D., Malhotra, R., Ravi, B., & Sindhurani, P. (2010) · Current Oncology · doi:10.3747/co.v17i1.356 · Cited by 250
Essential and overlapping functions for mammalian Argonautes in microRNA silencing
Su, H., Trombly, M. I., Chen, J., & Wang, X. (2009) · Genes & Development · doi:10.1101/gad.1749809 · Cited by 238
“Another type of off-target effect is due to the overloading of the endogenous miRNA pathway (Grimm et al. 2006).”
BackgroundModulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?
Tong, A. W., & Nemunaitis, J. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.8 · Cited by 250
MicroRNA and 3T3-L1 pre-adipocyte differentiation
Kajimoto, K., Naraba, H., & Iwai, N. (2006) · RNA · doi:10.1261/rna.7228806 · Cited by 236
Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma
Chiosea, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R. W., & Dacic, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3533 · Cited by 241
“(23), short hairpin RNA (shRNA) expression in hepatocytes after i.”
Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors
Wang, H., Jiang, Y., Peng, H., Chen, Y., Zhu, P., & Huang, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.031 · Cited by 231
Miller, S. C., Miyata, K., Brown, S. J., & Tomoyasu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047431 · Cited by 216
“Because miRNAs are essential for growth, development, and tissue homeostasis, this inhibition may result in lethality [50,54].”
BackgroundDelivery Vehicles for Small Interfering RNA In Vivo
de Fougerolles, A. R. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.928 · Cited by 226
Rossi, J. J., June, C. H., & Kohn, D. B. (2007) · Nature Biotechnology · doi:10.1038/nbt1367 · Cited by 231
“The expression levels of shRNAs can be a critical determinant of whether they are toxic, so caution is necessary in using expressed shRNAs for gene therap”
BackgroundHydrophobization and bioconjugation for enhanced siRNA delivery and targeting
De Paula, D., Bentley, M. V. L. B., & Mahato, R. I. (2007) · RNA · doi:10.1261/rna.459807 · Cited by 228
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A., Fitzgerald, K., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 207
“Indeed, this was observed for short hairpin RNAs that were expressed under a strong promoter, which saturated the exportin molecule that transports precursor miRNAs (pre-miRNAs) from the nucleus to the cytoplasm 87,88 .”
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Zhang, S., Cheng, Z., Wang, Y., & Han, T. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s288859 · Cited by 211
Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA
Singh, S., Narang, A. S., & Mahato, R. I. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0608-1 · Cited by 220
p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer
Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F., Kastenhuber, E. R., Weissmueller, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.051 · Cited by 227
Loss-of-function genetic tools for animal models: cross-species and cross-platform differences
Housden, B. E., Muhar, M., Gemberling, M., Gersbach, C. A., Stainier, D. Y. R., Seydoux, G., Mohr, S. E., Zuber, J., & Perrimon, N. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.118 · Cited by 220
Djelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bièche, I., Marquer, C., Chali, F., Ayciriex, S., Auzeil, N., et al. (2015) · Brain · doi:10.1093/brain/awv166 · Cited by 223
“2B) or saturation of miRNA processing machinery (Grimm et al., 2006) (Supplementary Fig.”
BackgroundSmooth Muscle Enriched Long Noncoding RNA ( SMILR ) Regulates Cell Proliferation
Ballantyne, M. D., Pinel, K., Dakin, R., Vesey, A. T., Diver, L., Mackenzie, R., Garcia, R., Welsh, P., Sattar, N., Hamilton, G., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.021019 · Cited by 223
Akhtar, S., & Benter, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.010 · Cited by 219
Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay
Fellmann, C., Zuber, J., McJunkin, K., Chang, K., Malone, C. D., Dickins, R. A., Xu, Q., Hengartner, M. O., Elledge, S. J., Hannon, G. J., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.008 · Cited by 222
“In addition, high intracellular levels of synthetic small RNAs can result in toxicities related to saturation of the RNAi machinery (Grimm et al., 2006).”
Host-virus interaction: a new role for microRNAs
Scaria, V., Hariharan, M., Maiti, S., Pillai, B., & Brahmachari, S. K. (2006) · Retrovirology · doi:10.1186/1742-4690-3-68 · Cited by 220
“Recent evidence also suggests an overdose of artificial short hairpin RNAs (shR-NAs) can saturate the RNA interference machinery [ 17 ].”
BackgroundDann, C. T., Alvarado, A. L., Molyneux, L. A., Denard, B. S., Garbers, D. L., & Porteus, M. H. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0134 · Cited by 214
New Avenues for the Treatment of Huntington’s Disease
Kim, A., Lalonde, K., Truesdell, A., Gomes Welter, P., Brocardo, P. S., Rosenstock, T. R., & Gil-Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 191
“Although shRNAs are generally considered toxic due to the saturation of the miRINA biogenesis pathway [421,422], when compared with siRNAs, shRNAs may be less toxic due to the fewer “off-target” effects and the longer-lasting approach.”
BackgroundCrosstalk between TGF-β signaling and the microRNA machinery
Butz, H., Rácz, K., Hunyady, L., & Patócs, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.003 · Cited by 215
Gujrati, M., Malamas, A., Shin, T., Jin, E., Sun, Y., & Lu, Z.-R. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400787s · Cited by 206
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron
Liu, Y. P., Haasnoot, J., ter Brake, O., Berkhout, B., & Konstantinova, P. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn109 · Cited by 210
“Furthermore, using an RNA polymerase II promoter will allow lower and regulated expression, thereby reducing the risk of toxicity due to oversaturation of the RNAi machinery (46).”
Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
Shukla, S., Sumaria, C. S., & Pradeepkumar, P. I. (2010) · ChemMedChem · doi:10.1002/cmdc.200900444 · Cited by 210
Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskämper, J., Westermann, D., Bisping, E., Ly, H., Wang, X., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.783852 · Cited by 212
Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi Therapeutic
Giering, J. C., Grimm, D., Storm, T. A., & Kay, M. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.144 · Cited by 206
Self-citationThe Roles of Cyclin A2, B1, and B2 in Early and Late Mitotic Events
Gong, D., & Ferrell, J. E. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-05-0393 · Cited by 192
“, 2006), their lack of interference with endogenous miRNA processing pathways (Grimm et al., 2006), and their record of specificity and efficacy in previous screens and studies (Myers et al.”
BackgroundInfluentialSequence-non-specific effects of RNA interference triggers and microRNA regulators
Olejniczak, M., Galka, P., & Krzyzosiak, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp829 · Cited by 202
“The toxicity of reagents of RNAi and miRNA technologies may have different sources: (i) saturation of cellular proteins involved in RNAi and miRNA pathways (70,71), (ii) sequence-specific targeting of other, unintended transcripts (off-target effect) (72,73) and (iii) sequence-non-specific activation of cellular senso…”
BackgroundRecent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“liver cell transduction, rAAV-9 for cardiac and rAAV-1 for muscle cell transduction [9,101–105].”
BackgroundGene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Knocking down Disease with siRNAs
Dykxhoorn, D. M., & Lieberman, J. (2006) · Cell · doi:10.1016/j.cell.2006.07.007 · Cited by 197
“Copiously expressing microRNA-like shRNAs, either using a virus (Lu and Cullen, 2004) or gene therapy vector (Grimm et al., 2006), interferes with endogenous microRNA nuclear export by exportin 5.”
BackgroundPuar, Y., Shanmugam, M., Fan, L., Arfuso, F., Sethi, G., & Tergaonkar, V. (2018) · Biomedicines · doi:10.3390/biomedicines6030082 · Cited by 197
“However, it must also be noted that vector-based, sustained high-level delivery of siRNAs can lead to dose-dependent liver injury and even death in mouse models [202].”
BackgroundTherapeutic potential for microRNAs
Esau, C. C., & Monia, B. P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.007 · Cited by 195
The MicroRNA Biology of the Mammalian Nucleus
Roberts, T. C. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.40 · Cited by 189
Grimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
“Knowing that Xpo-5 can limit shRNAs in mice (3), we now asked whether its stable expression in adult murine liver would suffice to alleviate shRNA hepatotoxicity and extend in vivo RNAi.”
BackgroundMethodResultSelf-citationTranscription factor RUNX1 promotes survival of acute myeloid leukemia cells
Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., Nakagawa, M., Olsson, A., Wunderlich, M., Link, K. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68557 · Cited by 196
“It has been shown that some shRNAs have off-target or nonspecific toxicity (28).”
Small silencing RNAs: State-of-the-art
Grimm, D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.002 · Cited by 185
Self-citationProgress and Prospects: The design and production of plasmid vectors
Gill, D. R., Pringle, I. A., & Hyde, S. C. (2009) · Gene Therapy · doi:10.1038/gt.2008.183 · Cited by 187
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“The first is significant vector loss and concerns of toxicity (Grimm et al., 2006) due to high off target peripheral biodistribution, especially to the liver, which can be somewhat reduced by restricting blood flow by occlusion (Bevan et al., 2011) or by choosing to express a therapeutic gene under…”
BackgroundQuantitative functions of Argonaute proteins in mammalian development
Wang, D., Zhang, Z., O'Loughlin, E., Lee, T., Houel, S., O'Carroll, D., Tarakhovsky, A., Ahn, N. G., & Yi, R. (2012) · Genes & Development · doi:10.1101/gad.182758.111 · Cited by 179
“Because Xpo5 is easily saturated, and this dampens miRNA biogenesis (Yi et al. 2005; Grimm et al. 2006), it indicates a stringent requirement for the high level of Xpo5 expression by the miRNA pathway.”
BackgroundPartial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis
Yang, C., Wang, H., Qiao, T., Yang, B., Aliaga, L., Qiu, L., Tan, W., Salameh, J., McKenna-Yasek, D. M., Smith, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322641111 · Cited by 185
“Notwithstanding the absence of the rescue experiment, it is unlikely that a nonspecific effect caused the motor neuron degeneration and ALS phenotype because such an effect is observed only in extremely high levels of siRNA or shRNA expression conditions (58, 59).”
BackgroundCationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S.-H., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 173
Prediction of potent shRNAs with a sequential classification algorithm
Pelossof, R., Fairchild, L., Huang, C.-H., Widmer, C., Sreedharan, V. T., Sinha, N., Lai, D.-Y., Guan, Y., Premsrirut, P. K., Tschaharganeh, D. F., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3807 · Cited by 183
Stress-induced changes in miRNA biogenesis and functioning
Olejniczak, M., Kotowska-Zimmer, A., & Krzyzosiak, W. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2591-0 · Cited by 172
“More than a decade ago, the Kay group reported that the overexpression of artificial pre-miRNAs (short hairpin RNAs) in the liver of adult mice saturates the miRNA biogenesis pathway at the EXP-5 step [90].”
BackgroundDisruption of Dicer1 Induces Dysregulated Fetal Gene Expression and Promotes Hepatocarcinogenesis
Sekine, S., Ogawa, R., Ito, R., Hiraoka, N., McManus, M. T., Kanai, Y., & Hebrok, M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.067 · Cited by 181
Chitosan for Gene Delivery and Orthopedic Tissue Engineering Applications
Raftery, R., O'Brien, F., & Cryan, S.-A. (2013) · Molecules · doi:10.3390/molecules18055611 · Cited by 173
“RNAi dose is even more critical as high doses can overwhelm the RNAi machinery of cells by blocking or increasing the expression of other miRNAs or causing cell death by RNAi-mediated toxicity [109,110].”
BackgroundTherapeutic MicroRNA Strategies in Human Cancer
Li, C., Feng, Y., Coukos, G., & Zhang, L. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9145-9 · Cited by 177
“endogenous miRNA precursor processing leads to the downregulation of liver-derived miRNAs and consequently morbidity (95).”
BackgroundMicroRNAs in adipose tissue: their role in adipogenesis and obesity
Hilton, C., Neville, M. J., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.59 · Cited by 174
Kang, H., Ga, Y. J., Kim, S. H., Cho, Y. H., Kim, J. W., Kim, C., & Yeh, J.-Y. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00981-9 · Cited by 163
“This strategy circumvents the engagement of Dicer-induced mechanisms [78] and abrogates protein expression when long pieces (> 30 nucleotides) of dsRNA interact with intracellular RNA receptors [140].”
BackgroundChen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176
“In mammalian systems, Dicer, the dsRNA-binding proteins TARBP2 and/or PACT, and an Ago protein appear to form the RISC-loading complex (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Maniataki and Mourelatos 2005; Lee et al. 2006).”
BackgroundPotential pharmacological control of the NF-κB pathway
Sethi, G., & Tergaonkar, V. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.004 · Cited by 171
microRNA: Emerging therapeutic targets in acute ischemic diseases
Fasanaro, P., Greco, S., Ivan, M., Capogrossi, M. C., & Martelli, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.003 · Cited by 174
“In fact, robust over-expression of an shRNA by an adeno-associated virus induced the downregulation of liver-derived miRNAs, liver injury and death of treated mice (Grimm et al., 2006).”
MicroRNA: an Emerging Therapeutic Target and Intervention Tool
Liu, Z., Sall, A., & Yang, D. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9060978 · Cited by 173
“It is not clear what the mechanism of miRNA reduction might be [64].”
BackgroundInfluentialTissue-specific and reversible RNA interference in transgenic mice
Dickins, R. A., McJunkin, K., Hernando, E., Premsrirut, P. K., Krizhanovsky, V., Burgess, D. J., Kim, S. Y., Cordon-Cardo, C., Zender, L., Hannon, G. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2045 · Cited by 174
“In developing this approach, we were concerned that the levels of tet transactivator produced in existing mouse strains would be insufficient to drive functional shRNA expression or, alternatively, that overexpression of the exogenous microRNA would saturate the RNAi machinery leading to off-target effects as has rece…”
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference
Barrangou, R., Birmingham, A., Wiemann, S., Beijersbergen, R. L., Hornung, V., & Smith, A. V. B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv226 · Cited by 165
RNAi for Insect Control: Current Perspective and Future Challenges
Katoch, R., Sethi, A., Thakur, N., & Murdock, L. L. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0399-4 · Cited by 161
“result in lethality [39, 120].”
RNA Interference and Cancer Therapy
Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0604-5 · Cited by 167
Eguchi, T., Watanabe, K., Hara, E. S., Ono, M., Kuboki, T., & Calderwood, S. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058796 · Cited by 169
“Exportin-5 subsequently exports the pre-miRNA to the cytoplasm [1,2].”
BackgroundDoege, H., Grimm, D., Falcon, A., Tsang, B., Storm, T. A., Xu, H., Ortegon, A. M., Kazantzis, M., Kay, M. A., & Stahl, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803510200 · Cited by 169
Self-citationLentiviral delivery of short hairpin RNAs
Manjunath, N., Wu, H., Subramanya, S., & Shankar, P. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.004 · Cited by 165
“expression, leading to lethality in mice [64].”
Stable RNA interference rules for silencing
Fellmann, C., & Lowe, S. W. (2014) · Nature Cell Biology · doi:10.1038/ncb2895 · Cited by 163
Herold, M. J., van den Brandt, J., Seibler, J., & Reichardt, H. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806213105 · Cited by 169
“It was previously reported that high siRNA levels might exert toxic effects because of an overloading of the cellular RNAi machinery (24).”
BackgroundRNAi-based nanomedicines for targeted personalized therapy
Daka, A., & Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.014 · Cited by 167
RNAi-Based Biocontrol Products: Market Status, Regulatory Aspects, and Risk Assessment
Schutter, K. D., Taning, C. N. T., Daele, L. V., Damme, E. J. M. V., Dubruel, P., & Smagghe, G. J. (2022) · Frontiers in Insect Science · doi:10.3389/finsc.2021.818037 · Cited by 172
“While in mice, saturation of the RNAimachinery was found to cause lethality (46), this has not yet been reported in arthropods (39).”
BackgroundPan, Q., Ramakrishnaiah, V., Henry, S., Fouraschen, S., de Ruiter, P. E., Kwekkeboom, J., Tilanus, H. W., Janssen, H. L. A., & van der Laan, L. J. W. (2012) · Gut · doi:10.1136/gutjnl-2011-300449 · Cited by 164
“However, AAV-mediated expression of shRNA was shown to evoke liver toxicity in mice, ultimately causing death.(36) It was suggested that the saturation of the endogenous miRNA processing machinery by overexpressed shRNA is the potential cause,(40) but the exact mechanism remains unclear.”
BackgroundDieckhoff, B., Petersen, B., Kues, W. A., Kurth, R., Niemann, H., & Denner, J. (2008) · Xenotransplantation · doi:10.1111/j.1399-3089.2008.00442.x · Cited by 164
“The efficacy of RNAi has been investigated in vivo, until now mainly in mice, rats, and cattles [48–52].”
BackgroundPolycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions
Ballarín-González, B., & Howard, K. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.004 · Cited by 162
Gene networks and the neuroendocrine regulation of puberty
Ojeda, S. R., Dubay, C., Lomniczi, A., Kaidar, G., Matagne, V., Sandau, U. S., & Dissen, G. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.12.003 · Cited by 156
“…to siRNAs, shRNAs delivered as integral part of a miRNA can be processed by the cellular machinery as if they were endogenous miRNAs, thus avoiding cellular toxicity caused by oversaturation of the pathway that processes miRNAs into functional siRNAs (Boudreau et al., 2009; Grimm et al., 2006).”
BackgroundLauring, J., Abukhdeir, A. M., Konishi, H., Garay, J. P., Gustin, J. P., Wang, Q., Arceci, R. J., Matsui, W., & Park, B. H. (2008) · Blood · doi:10.1182/blood-2007-05-088674 · Cited by 157
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs
Boudreau, R. L., Monteys, A. M., & Davidson, B. L. (2008) · RNA · doi:10.1261/rna.1062908 · Cited by 163
“Instability (i.e., single-stranded nature) within the gray-shaded region may promote Drosha binding and cleavage (Zeng and Cullen 2005; Han et al. 2006).”
BackgroundMicroRNA-Based Therapeutics for Cancer
Wang, V., & Wu, W. (2009) · BioDrugs · doi:10.2165/00063030-200923010-00002 · Cited by 158
Transgenic RNAi Depletion of Claudin-16 and the Renal Handling of Magnesium
Hou, J., Shan, Q., Wang, T., Gomes, A. S., Yan, Q., Paul, D. L., Bleich, M., & Goodenough, D. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700632200 · Cited by 159
Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma
Erkizan, H. V., Uversky, V. N., & Toretsky, J. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2261 · Cited by 160
Cyclin A2 Regulates Nuclear-Envelope Breakdown and the Nuclear Accumulation of Cyclin B1
Gong, D., Pomerening, J. R., Myers, J. W., Gustavsson, C., Jones, J. T., Hahn, A. T., Meyer, T., & Ferrell, J. E. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.066 · Cited by 160
Franich, N. R., Fitzsimons, H. L., Fong, D. M., Klugmann, M., During, M. J., & Young, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.50 · Cited by 157
A pipeline for the generation of shRNA transgenic mice
Dow, L. E., Premsrirut, P. K., Zuber, J., Fellmann, C., McJunkin, K., Miething, C., Park, Y., Dickins, R. A., Hannon, G. J., & Lowe, S. W. (2012) · Nature Protocols · doi:10.1038/nprot.2011.446 · Cited by 159
“Expression at the single-copy level is beneficial as it avoids the complications of shRNA toxicity and/or saturation apparent in other setting”
BackgroundFunctional Importance of Dicer Protein in the Adaptive Cellular Response to Hypoxia
Ho, J. J. D., Metcalf, J. L., Yan, M. S., Turgeon, P. J., Wang, J. J., Chalsev, M., Petruzziello-Pellegrini, T. N., Tsui, A. K. Y., He, J. Z., Dhamko, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373365 · Cited by 156
“This suggests that even though Exportin-5 can be rate-limiting in certain settings (21) we failed to define a major functional delay in the nuclear/cytoplasmic transport of pre-microRNAs, which is a known function of Exportin-5.”
BackgroundGene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia
Ng, R., Wu, H., Xiao, H., Chen, X., Willenbring, H., Steer, C. J., & Song, G. (2014) · Hepatology · doi:10.1002/hep.27153 · Cited by 154
“For this purpose, we used a double-stranded AAV vector that affords more rapid and efficient transgene expression than conventional AAV vectors by bypassing the need for conversion from a single-stranded to a doublestranded state after transduction.(32) To restrict Cre expression to hepatocytes, we used a hepatocytesp…”
MethodStable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates
An, D. S., Donahue, R. E., Kamata, M., Poon, B., Metzger, M., Mao, S.-H., Bonifacino, A., Krouse, A. E., Darlix, J.-L., Baltimore, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705474104 · Cited by 151
Shimizu, S., Hong, P., Arumugam, B., Pokomo, L., Boyer, J., Koizumi, N., Kittipongdaja, P., Chen, A., Bristol, G., Galic, Z., et al. (2010) · Blood · doi:10.1182/blood-2009-04-215855 · Cited by 150
The molecular landscape of ETMR at diagnosis and relapse
Lambo, S., Gröbner, S. N., Rausch, T., Waszak, S. M., Schmidt, C., Gorthi, A., Romero, J. C., Mauermann, M., Brabetz, S., Krausert, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1815-x · Cited by 156
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 157
“This has the advantage that they are less likely to interfere with gene regulation by endogenous miRNAs (Grimm et al , 2006). siRNA drugs face similar challenges as ASOs in terms of delivery, stability, and immunogenicity.”
RNAi for revealing and engineering plant gene functions
Small, I. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.01.012 · Cited by 151
“This has again been observed in animal systems [33], but there are no published reports so far of this effect in plants.”
BackgroundTherapeutic application of RNAi: is mRNA targeting finally ready for prime time?
Grimm, D., & Kay, M. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34129 · Cited by 172
Self-citationA Direct In Vivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration
Wuestefeld, T., Pesic, M., Rudalska, R., Dauch, D., Longerich, T., Kang, T.-W., Yevsa, T., Heinzmann, F., Hoenicke, L., Hohmeyer, A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.026 · Cited by 149
Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis
Yang, Y.-S., Xie, J., Wang, D., Kim, J.-M., Tai, P. W. L., Gravallese, E., Gao, G., & Shim, J.-H. (2019) · Nature Communications · doi:10.1038/s41467-019-10809-6 · Cited by 139
Next-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
Self-citationThe Use of Nanoparticulates to Treat Breast Cancer
Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., KESTER, M. A., Meyers, C., Jiang, Y., & Adair, J. H. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0202 · Cited by 152
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway
John, M., Constien, R., Akinc, A., Goldberg, M. S., Moon, Y.-A., Spranger, M., Hadwiger, P., Soutschek, J., Vornlocher, H., Manoharan, M., et al. (2007) · Nature · doi:10.1038/nature06179 · Cited by 144
Unpacking extracellular vesicles: RNA cargo loading and function
Dellar, E. R., Hill, C., Melling, G. E., Carter, D. R. F., & Baena-López, L. A. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.40 · Cited by 158
“…for example, that bulk EV miRNA delivery mediates a non-specific effect, by effectively ‘drowning out’ low abundance miRNAs in the recipient cells, so that they can no longer compete for binding to the RISC complex, an effect seen previously for shRNA (Brown et al., 2007; Grimm et al., 2006).”
BackgroundmicroRNAs: a new emerging class of players for disease diagnostics and gene therapy
Zhang, B., & Farwell, M. A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00196.x · Cited by 157
“A recent study demonstrated that overexpression of shRNA in mice saturated the miRNA pathway and caused severe toxicity in liver [162].”
Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference
Borel, F., Kay, M. A., & Mueller, C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.285 · Cited by 142
Self-citationPastore, N., Blomenkamp, K., Annunziata, F., Piccolo, P., Mithbaokar, P., Maria Sepe, R., Vetrini, F., Palmer, D., Ng, P., Polishchuk, E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202046 · Cited by 142
“However, shRNA delivered by gene therapy vectors has raised concerns because severe toxicity and lethality have been reported in mice (Grimm et al, 2006). shRNA-mediated saturation of the exportin-5 pathway, which shuttles cellular micro-RNA (miRNA) from nucleus to cyto-plasm, has been proposed as…”
Gene Therapy for Heart Failure
Tilemann, L., Ishikawa, K., Weber, T., & Hajjar, R. J. (2012) · Circulation Research · doi:10.1161/circresaha.111.252981 · Cited by 140
Alu element‐containing RNA s maintain nucleolar structure and function
Caudron‐Herger, M., Pankert, T., Seiler, J., Németh, A., Voit, R., Grummt, I., & Rippe, K. (2015) · The EMBO Journal · doi:10.15252/embj.201591458 · Cited by 140
“The alu RNA and L1-repeat sequences were introduced into the pBS/U6 plasmid expressing either GFP or TagRFP using two BbsI restriction sites (Grimm et al , 2006).”
Altering the immune response with lipid-based nanoparticles
Landesman‐Milo, D., & Peer, D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.034 · Cited by 148
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.